Related references
Note: Only part of the references are listed.Human chimeric antigen receptor macrophages for cancer immunotherapy
Michael Klichinsky et al.
NATURE BIOTECHNOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
Camilla Salvagno et al.
NATURE CELL BIOLOGY (2019)
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release
Shu Lian et al.
EBIOMEDICINE (2019)
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C. A. Gomez-Roca et al.
ANNALS OF ONCOLOGY (2019)
CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages
Zihui Yang et al.
FRONTIERS IN ONCOLOGY (2019)
Cellular therapy: Immune-related complications
Joseph H. Oved et al.
IMMUNOLOGICAL REVIEWS (2019)
Tumor Microenvironment as A Game Changer in Cancer Radiotherapy
Magdalena Jarosz-Biej et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira A. Barkal et al.
NATURE (2019)
TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages
Yang Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia
C. K. Brierley et al.
TRANSFUSION (2019)
SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma
Ya-Ping Chen et al.
BLOOD CANCER JOURNAL (2019)
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
Eleanor M. Scott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model
Fatemeh Tahmasebi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
Eric Hatterer et al.
MABS (2019)
CD20-selective inhibition of CD47-SIRP alpha don't eat me signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Peter E. van Bommel et al.
ONCOIMMUNOLOGY (2018)
3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment
Sofia P. Rebelo et al.
BIOMATERIALS (2018)
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Yu Wang et al.
CANCER LETTERS (2018)
Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma
Remi Adelaiye-Ogala et al.
CANCER RESEARCH (2018)
Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers
Sara Nikoofal-Sahlabadi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Implications of macrophage polarization in autoimmunity
Samanta C. Funes et al.
IMMUNOLOGY (2018)
Macrophage plasticity, polarization, and function in health and disease
Abbas Shapouri-Moghaddam et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
Chimeric antigen receptors that trigger phagocytosis
Meghan A. Morrissey et al.
ELIFE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Amira A. Barkal et al.
NATURE IMMUNOLOGY (2018)
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies
Daniela F. Quail et al.
CLINICAL CANCER RESEARCH (2017)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
Cancer immunotherapy targeting the CD47/SIRPα axis
Kipp Weiskopf
EUROPEAN JOURNAL OF CANCER (2017)
CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia
Jun Liu et al.
IMMUNOTHERAPY (2017)
Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis
Benjamin P. Sinder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Targeting hepatic macrophages to treat liver diseases
Frank Tacke
JOURNAL OF HEPATOLOGY (2017)
Macrophages as Key Drivers of Cancer Progression and Metastasis
Sebastian R. Nielsen et al.
MEDIATORS OF INFLAMMATION (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Nan Guo Ring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
PSGL-1: A New Player in the Immune Checkpoint Landscape
Roberto Tinoco et al.
TRENDS IN IMMUNOLOGY (2017)
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
Melinda Mata et al.
CANCER DISCOVERY (2017)
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
Karla R. Wiehagen et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Fumi Sato-Kaneko et al.
JCI INSIGHT (2017)
SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors
Cory M. Alvey et al.
CURRENT BIOLOGY (2017)
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
Lekh N. Dahal et al.
CANCER RESEARCH (2017)
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy
Tadahiko Yanagita et al.
JCI INSIGHT (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Murine macrophage response from peritoneal cavity requires signals mediated by chemokine receptor CCR-2 during Staphylococcus aureus infection
Ajeya Nandi et al.
IMMUNOLOGIC RESEARCH (2016)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2016)
Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model
Chenran Zhang et al.
BIOMATERIALS (2016)
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis
Mathias Wenes et al.
CELL METABOLISM (2016)
STAT3 signaling in immunity
Emily J. Hillmer et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
Roberto Tinoco et al.
IMMUNITY (2016)
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
Vinit Kumar et al.
IMMUNITY (2016)
The molecular mechanisms of TLR-signaling cooperation in cytokine regulation
Qian Liu et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions
Ryan A. Ortega et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects
F. Piaggio et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Leon P. Pradel et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models
Takuhiro Shoji et al.
NEURO-ONCOLOGY (2016)
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
Heleen. H. Van Acker et al.
PHARMACOLOGY & THERAPEUTICS (2016)
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Daniela F. Quail et al.
SCIENCE (2016)
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Chiara Caparello et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki et al.
CELL REPORTS (2016)
Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities
Ana Teresa Pinto et al.
SCIENTIFIC REPORTS (2016)
A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
Branimir I. Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
CAR T-cell therapy: toxicity and the relevance of preclinical models
Milena Kalaitsidou et al.
IMMUNOTHERAPY (2015)
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Emily C. Piccione et al.
MABS (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Contribution of metabolic reprogramming to macrophage plasticity and function
Karim C. EL Kasmi et al.
SEMINARS IN IMMUNOLOGY (2015)
CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment
Qian-Qian Zhang et al.
SCIENTIFIC REPORTS (2015)
Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
Daniele Minardi et al.
CURRENT UROLOGY REPORTS (2015)
Cellular Metabolism and Macrophage Functional Polarization
Linnan Zhu et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2015)
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
Elisa Gomez Perdiguero et al.
NATURE (2015)
STING: infection, inflammation and cancer
Glen N. Barber
NATURE REVIEWS IMMUNOLOGY (2015)
The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
A. Neil Barclay et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
In Vitro Evaluation of Inhibitory Effect of Nuclear Factor-KappaB Activity by Small Interfering RNA on Pro-tumor Characteristics of M2-Like Macrophages
Yusuke Kono et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2014)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Parag P. Patwardhan et al.
CLINICAL CANCER RESEARCH (2014)
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray et al.
IMMUNITY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Role of spleen-derived monocytes/macrophages in acute ischemic brain injury
Eunhee Kim et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2014)
CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile
Elena Sierra-Filardi et al.
JOURNAL OF IMMUNOLOGY (2014)
Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers
Francois Moisan et al.
MOLECULAR ONCOLOGY (2014)
Radiotherapy and the tumor stroma: the importance of dose and fractionation
Turid Hellevik et al.
FRONTIERS IN ONCOLOGY (2014)
Interleukin-4-and Interleukin-13-Mediated Alternatively Activated Macrophages: Roles in Homeostasis and Disease
Steven J. Van Dyken et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
Andrea Casazza et al.
CANCER CELL (2013)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer
Jingying Xu et al.
CANCER RESEARCH (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Simon Yona et al.
IMMUNITY (2013)
The Adenosine-Dependent Angiogenic Switch of Macrophages to an M2-Like Phenotype is Independent of Interleukin-4 Receptor Alpha (IL-4Rα) Signaling
Christopher James Ferrante et al.
INFLAMMATION (2013)
Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer
Daniel W. Vermeer et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells
Debbie C. Strachan et al.
ONCOIMMUNOLOGY (2013)
Thymosin α1 and cancer: action on immune effector and tumor target cells
Enrico Garaci et al.
THYMOSINS IN HEALTH AND DISEASE I (2012)
Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
David A. Hume et al.
BLOOD (2012)
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Elizabeth S. Nakasone et al.
CANCER CELL (2012)
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment
P. Allavena et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Zhen Huang et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
D. Kim et al.
LEUKEMIA (2012)
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
John C. Byrd et al.
LEUKEMIA & LYMPHOMA (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Effect of CpG ODN on monocytic myeloid derived suppressor cells
Hidekazu Shirota et al.
ONCOIMMUNOLOGY (2012)
Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+T cell response in patients with metastatic esophageal squamous cell carcinoma
Makoto Iwahashi et al.
CANCER SCIENCE (2010)
Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang et al.
CLINICAL CANCER RESEARCH (2010)
Alternative Activation of Macrophages: Mechanism and Functions
Siamon Gordon et al.
IMMUNITY (2010)
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
E. Oflazoglu et al.
BRITISH JOURNAL OF CANCER (2009)
gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
Julia Bollrath et al.
CANCER CELL (2009)
Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β
Taku Nagai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy
Marcin Kortylewski et al.
CANCER RESEARCH (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
Filip K. Swirski et al.
SCIENCE (2009)
Functions and molecular mechanisms of the CD47-SIRPα signalling pathway
Takashi Matozaki et al.
TRENDS IN CELL BIOLOGY (2009)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
Brian K. Link et al.
JOURNAL OF IMMUNOTHERAPY (2006)
The chemokine system in diverse forms of macrophage activation and polarization
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2004)
Role of CD47 as a marker of self on red blood cells
PA Oldenborg et al.
SCIENCE (2000)
Share Paper
